Rulonilimab | m-entrepreneurship.com

Product Name :
Rulonilimab

Search keywords :
Rulonilimab

drugId :
null

Target Vo:
Programmed cell death protein 1

Target Vo Short Name :
PD-1

Moa_Name:
Programmed cell death protein 1 blockers

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shandong New Time Pharmaceutical Co Ltd

Active Company_Name :
Shandong New Time Pharmaceutical Co Ltd

Active Indication_Name:
Carcinoma, Hepatocellular

In Active Indication_Name:
Lymphoma, Large B-Cell, Diffuse

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FXR1 Antibody
FACL4 Antibody
Epac1 Antibody: Epac1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 104 kDa, targeting to Epac1. It can be used for WB,IHC-P,IP,ICC/IF assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts